title: Kidney cancer: in crossover study, patients and physicians prefer pazopanib.
authors.forename: Robert
authors.initials: R
authors.lastname: Phillips
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D057240:Patient Preference; D011743:Pyrimidines / Q000009:adverse effects*; D011758:Pyrroles / Q000009:adverse effects*; D013449:Sulfonamides / Q000009:adverse effects*
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011743:Pyrimidines; D011758:Pyrroles; D013449:Sulfonamides
references.citation: J Clin Oncol. 2014 May 10;32(14):1412-8
references.pmid: 24687826